country

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-184331

Copy Link Print Information

FAAH-IN-10

FAAH-IN-10 is a FAAH inhibitor and TRPV1 antagonist, with an IC₅₀ of 0.57 μM against human FAAH. FAAH-IN-10 regulates FAAH activity, antagonizes TRPV1 activity, and exhibits analgesic and anti-inflammatory activities. FAAH-IN-10 does not induce TRPV1-mediated hyperthermia. FAAH-IN-10 can be used for pain-related research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Formel: C₂₄H₂₅N₃O₃S
Molecular Weight:435.54

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

FAAH-IN-10 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

TRPV1

Alle TRP Channel Isoform-spezifische Produkte anzeigen :

In Vitro

FAAH-IN-10 (Compound 31) potently inhibits capsaicin-induced activation of human TRPV1-transfected HEK-293 cells with an IC₅₀ of 18.81 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

FAAH-IN-10 (Compound 31) (10-40 mg/kg; i.p.; single dose) produces dose-dependent analgesic effects in a formalin-induced pain model, with significant reductions in licking/biting time at doses as low as 10 mg/kg^[1].
FAAH-IN-10 (5-20 mg/kg; i.p.; single dose) demonstrates dose-dependent anti-inflammatory activity in a carrageenan-induced paw edema model, with greater efficacy than AA-5-HT at equivalent and higher doses^[1].
FAAH-IN-10 (5 mg/kg; i.p.; single dose) does not induce TRPV1-mediated hyperthermia in mice at therapeutic doses, maintaining stable core body temperature comparable to vehicle controls^[1].
FAAH-IN-10 (10-40 mg/kg; i.p.; single dose) produces dose-dependent analgesia mediated by TRPV1 antagonism in a capsaicin-induced pain model^[1].
FAAH-IN-10 (30 mg/kg; i.p.; single dose) exerts part of its analgesic effect via FAAH inhibition, as demonstrated by reversal of efficacy with the CB₁ receptor antagonist AM251^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Kunming mice (male, 22-35 g)^[1]
Dosage:

10 mg/kg; 20 mg/kg; 30 mg/kg; 40 mg/kg
Administration:

i.p.; single dose
Result:

Significantly reduced licking/biting time in both phase I and phase II at 30 mg/kg, with greater efficacy than positive control AA-5-HT.
Reduced phase II licking/biting time in a dose-dependent manner at 10, 20, and 40 mg/kg.
Significantly reduced phase I licking/biting time compared to vehicle at 40 mg/kg.

Animal Model:

unstated strain^[1]
Dosage:

5 mg/kg; 10 mg/kg; 20 mg/kg
Administration:

i.p.; single dose
Result:

Exhibited superior anti-edema effects relative to AA-5-HT (5 mg/kg) at 5, 10, and 20 mg/kg.
Showed a clear dose-response relationship, with escalating doses producing progressively greater inhibition of paw edema.

Animal Model:

unstated strain^[1]
Dosage:

5 mg/kg; graded unspecified doses
Administration:

i.p.; single dose
Result:

Did not produce a statistically significant increase in core body temperature at any time point up to 180 minutes post-injection, unlike BCTC.
Showed no significant differences in rectal temperature between compound 31-treated groups and vehicle group at all assessed time points in follow-up dose-ranging study.

Animal Model:

Kunming mice (male, 22-35 g)^[1]
Dosage:

10 mg/kg; 20 mg/kg; 40 mg/kg
Administration:

i.p.; single dose
Result:

Significantly reduced licking duration in a dose-dependent manner, with greater reductions observed at higher doses.

Animal Model:

Kunming mice (male, 22-35 g)^[1]
Dosage:

30 mg/kg
Administration:

i.p.; single dose
Result:

Significantly shortened formalin-induced phase II licking/biting time compared to vehicle.
Had its analgesic effect reversed by pretreatment with AM251, which significantly prolonged licking/biting duration.

Chemical Information

Molecular Weight 435.54
Formel C₂₄H₂₅N₃O₃S
SMILES

O=C(OC1=CC=CC=C1)NCCCC(N2[C@H](C3=NC(C4=CC=CC=C4)=CS3)CCC2)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Chen Y, et al. Structure-guided discovery of phenyl-carbamates as novel dual TRPV1 antagonists/FAAH inhibitors. Bioorganic chemistry. 2026 May 29;180:110058.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Angebot einholen Auf Lager